COVID-19 (SARS-CoV-2 infection) Infections and Infestations
Conditions
Interventions
The researchers are taking blood samples by the process of phlebotomy and taking nasal swabs using the usual nasal swab kits and saliva collection using commercially available basic saliva collection
Sponsors
University of Birmingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients and volunteers who have been tested for SARS-CoV-2 infection (both positive and negative for infection) and a matched control group
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Presence of immune response to SARS-CoV-2 measured using enzyme-linked immunosorbent assay (ELISA) and direct solid-state protein-binding assays such as Meso Scale Discovery (MSD) at various timepoints depending on the patient 2. Immunological and biological response to SARS-CoV-2 infection and its correlation with clinical outcome, measured using flow cytometry, proteomic analyses and functional studies at various timepoints depending on the patient | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Outcome results
None listed